CS-1092
|
|
|
- CAS號(hào):
- 837364-57-5
- 英文名:
- AG-024322
- 英文別名:
- CS-1092;AG-24322;AG-024322;AG024322; AG-024322;5-[3-(5,7-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl-3-Pyridinemethanamine;3-Pyridinemethanamine, 5-[3-(5,7-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl-;N-((5-((19E)-3-(4,6-DIFLUORO-2H-BENZO[D]IMIDAZOL-2-YLIDENE)-2,3-DIHYDRO-1H-INDAZOL-5-YL)-4-METHYLPYRIDIN-3-YL)METHYL)ETHANAMINE
- 中文名:
- CS-1092
- 中文別名:
- 化合物 T14136;化合物 AG-024322
- CBNumber:
- CB32668418
- 分子式:
- C23H20F2N6
- 分子量:
- 418.44
- MOL File:
- 837364-57-5.mol
|
|
|
CS-1092化學(xué)性質(zhì)
-
沸點(diǎn):
-
668.4±65.0 °C(Predicted)
-
|
-
密度:
-
1.361±0.06 g/cm3(Predicted)
-
|
-
儲(chǔ)存條件:
-
Store at -20°C
-
|
-
形態(tài):
-
Solid
-
|
-
酸度系數(shù)(pKa):
-
7.84±0.30(Predicted)
-
|
-
顏色:
-
White to off-white
-
|
CS-1092性質(zhì)、用途與生產(chǎn)工藝
AG-024322 是一種有效的 ATP 競(jìng)爭(zhēng)性的 pan-CDK 抑制劑，抑制 CDK1， CDK2， CDK4 的 Ki 值在 1-3 nM 范圍內(nèi)。AG-024322 在體內(nèi)表現(xiàn)出廣譜抗腫瘤活性和清晰的靶標(biāo)調(diào)控。AG-024322 誘導(dǎo)細(xì)胞凋亡 (apoptosis)。
|
COX-1
2.3 nM (Ki)
|
COX-2
3 nM (Ki)
|
COX-4
2.9 nM (Ki)
|
AG-024322 (0.1-30 μM; 24 hours) is less toxic at concentrations below 3 μM, the viability of human PBMCs as measured by ATP content with a TC
50
value of 1.4 μM for human PBMCs.AG-024322 (0-120 nM) exhibits growth inhibition effects on HCT-116 cells. It is slightly less potent in the functional cellular assay with an IC
50
of 120 nM.
AG-024322 (intravenous infusion; 2, 6, and 10 mg/kg; 5 days) exhibits no-adverse-effect at 2 mg/kg with mean plasma AUC (0-24.5) of 2.11 g.h/mL. At 6 mg/kg produces pancytic bone marrow hypocellularity, lymphoid depletion. And vascular injury at the injection site renal tubular degeneration occurs at 10 mg/kg.AG-024322 (20 mg/kg) inhibits the growth of established human tumor xenografts of different origins with tumor growth inhibition (TGI) ranging from 32% to 86.4%.It also exhibits anti-tumor effects as a dose-pdependent manner.AG-024322 (20 mg/kg) causes a 65% TGI in the MV522 tumor model. It results a 52% TGI at 1/2 of the maximum tolerated dose (MTD) and only slight anti-tumor activity at 1/4 of the MTD.
|
Animal Model:
|
Male and female cynomolgus monkeys
|
|
Dosage:
|
2, 6, and 10 mg/kg (Toxicity analysis)
|
|
Administration:
|
Intravenous infusion; 5 days
|
|
Result:
|
Resulted in dose-dependent pancytic bone marrow hypocellularity and lymphoid depletion in lymph nodes, spleen, and/or thymus at >6 mg/kg.
|
CS-1092
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS編號(hào) | 包裝 | 價(jià)格 |
|---|
| 2026/06/05 | HY-15491 | AG-024322 | 837364-57-5 | 1 mg | 2400元 |
| 2026/06/05 | HY-15491 | CS-1092
AG-024322 | 837364-57-5 | 5mg | 6000元 |
837364-57-5, CS-1092 相關(guān)搜索:
- 抑制劑
- C23H20F2N6
- 化合物 AG-024322
- 化合物 T14136
- 837364-57-5
- 3-Pyridinemethanamine, 5-[3-(5,7-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl-
- AG024322; AG-024322
- CS-1092
- AG-24322
- N-((5-((19E)-3-(4,6-DIFLUORO-2H-BENZO[D]IMIDAZOL-2-YLIDENE)-2,3-DIHYDRO-1H-INDAZOL-5-YL)-4-METHYLPYRIDIN-3-YL)METHYL)ETHANAMINE
- 5-[3-(5,7-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl-3-Pyridinemethanamine
- AG-024322